The Effect of L-Carnitine on Laboratory Findings in Critically Ill Children Admitted to the PICU.

The Effect of L-Carnitine Supplementation on Laboratory Findings in Critically Ill Children in the Pediatric Intensive Care Unit (PICU): A Triple-Blind, Randomized Controlled Trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221206056734N3

Enrollment

Registered

2025-03-27

Start date

2025-02-03

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill children admitted to the PICU. Failed or difficult intubation

Interventions

Intervention 1: Intervention group: 19 critically ill children admitted to the PICU will receive 50 to 100 mg/kg of liquid oral L-carnitine, produced by Pars Behrouzan Jam Company, along with tube fee

Eligibility

Sex/Gender

All

Age

1 Months to 12 Years

Inclusion criteria

Inclusion criteria: The age range of one month to 12 years. Critically Ill children are expected to stay in the PICU for more than 2 to 3 days. Legal guardian's consent.

Exclusion criteria

Exclusion criteria: Having liver or kidney diseases that contraindicate L-carnitine use. Children undergoing hemodialysis. Children undergoing chemotherapy. NPO patients who cannot start enteral nutrition.

Design outcomes

Primary

Measure	Time frame
Serum concentration of blood cells (White Blood Cells, Red Blood Cells, Neutrophils, Lymphocytes, and Serum Hemoglobin). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Nutritional biomarkers (Serum Albumin and Total Serum Protein). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum glycemic and lipid profile (Fasting Blood Glucose, Triglycerides, and HDL-Cholesterol). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Renal parameters (Sodium, Potassium, Calcium, Phosphorus, Magnesium, Creatinine, Urea, and Blood Urea Nitrogen (BUN)). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Coagulation factors (Platelet, Prothrombin (PT), Partial Thromboplastin Time (PTT), and International Normalized Ratio (INR)). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Liver parameters (Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Total Bilirubin, and Direct Bilirubin). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.	—

Measure

Time frame

Serum concentration of blood cells (White Blood Cells, Red Blood Cells, Neutrophils, Lymphocytes, and Serum Hemoglobin). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Nutritional biomarkers (Serum Albumin and Total Serum Protein). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Serum glycemic and lipid profile (Fasting Blood Glucose, Triglycerides, and HDL-Cholesterol). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Renal parameters (Sodium, Potassium, Calcium, Phosphorus, Magnesium, Creatinine, Urea, and Blood Urea Nitrogen (BUN)). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Coagulation factors (Platelet, Prothrombin (PT), Partial Thromboplastin Time (PTT), and International Normalized Ratio (INR)). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.;Liver parameters (Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Total Bilirubin, and Direct Bilirubin). Timepoint: Before the start of the intervention and 7 days after the start of the intervention. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Behrooz

Tabriz University of Medical Sciences

mm.behrooz@gmail.com+98 41 3159 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026